GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » EV-to-EBITDA

Cosciens Biopharma (TSX:CSCI) EV-to-EBITDA : 0.04 (As of May. 31, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cosciens Biopharma's enterprise value is C$-0.82 Mil. Cosciens Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was C$-21.46 Mil. Therefore, Cosciens Biopharma's EV-to-EBITDA for today is 0.04.

The historical rank and industry rank for Cosciens Biopharma's EV-to-EBITDA or its related term are showing as below:

TSX:CSCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -704.93   Med: 7.16   Max: 51.31
Current: 0.04

During the past 13 years, the highest EV-to-EBITDA of Cosciens Biopharma was 51.31. The lowest was -704.93. And the median was 7.16.

TSX:CSCI's EV-to-EBITDA is ranked better than
98.19% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs TSX:CSCI: 0.04

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), Cosciens Biopharma's stock price is C$4.80. Cosciens Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was C$-8.396. Therefore, Cosciens Biopharma's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Cosciens Biopharma EV-to-EBITDA Historical Data

The historical data trend for Cosciens Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma EV-to-EBITDA Chart

Cosciens Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.55 7.89 4.19 -2.19 0.41

Cosciens Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.77 2.52 0.69 0.41 0.14

Competitive Comparison of Cosciens Biopharma's EV-to-EBITDA

For the Biotechnology subindustry, Cosciens Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's EV-to-EBITDA falls into.


;
;

Cosciens Biopharma EV-to-EBITDA Calculation

Cosciens Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-0.818/-21.458
=0.04

Cosciens Biopharma's current Enterprise Value is C$-0.82 Mil.
Cosciens Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-21.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma  (TSX:CSCI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cosciens Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.80/-8.396
=At Loss

Cosciens Biopharma's share price for today is C$4.80.
Cosciens Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-8.396.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Cosciens Biopharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Executives
Dennis Turpin Director
Gilles Gagnon Director

Cosciens Biopharma Headlines

From GuruFocus